natgillin/translations-raw huggingface dataset:
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.4 and 5.2).
Preporučuje se oprez pri doziranju u bolesnika s teškim bubrežnim oštećenjem (klirens kreatinina < 30 ml/min) (vidjeti dijelove 4.4. i 5.2).
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance <30 ml/min) (see sections 4.2 and 5.2).
Preporučuje je oprez prilikom doziranja bolesnika s teškim oštećenjima bubrega (klirens kreatinina <30 ml/min) (vidjeti dijelove 4.2 i 5.2).
Caution is recommended when using travoprost in aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema.
Preporučuje se oprez kod primjene travoprosta u afakičnih bolesnika, pseudofakičnih bolesnika s rupturom stražnje kapsule leće ili intraokularnom lećom ugrađenom u prednju očnu sobicu, ili kod bolesnika s poznatim rizičnim faktorima za cistoidni edem makule.
Caution is recommended while using Kalydeco in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end-stage renal disease (see sections 4.4 and 5.2).
Preporučuje se oprez kod primjene lijeka Kalydeco u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina manji ili jednak 30 ml/min) ili u terminalnom stadiju bubrežne bolesti (vidjeti dijelove 4.4 i 5.2).
Caution is recommended, particularly in those patients with severe hepatic impairment (see section 4.4).
Preporučuje se oprez, osobito u onih bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.4).
Caution is required in patients who are treated concomitantly with valproate or other GHB dehydrogenase inhibitors as pharmacokinetic and pharmacodynamic interactions have been observed when sodium oxybate is co-administered with valproate (see section 4.5).
Potreban je oprez u bolesnika koji se istodobno liječe valproatom ili drugim inhibitorima GHB-dehidrogenaze budući da su opažene farmakokinetičke i farmakodinamičke interakcije kada se natrijev oksibat istodobno primjenjuje s valproatom (vidjeti dio 4.5).
Caution is required in treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalaemia (e.g., those on cardiac glycosides), or fluid retention (e.g., those with heart failure), severe or unstable angina pectoris, recent myocardial infarction or ventricular arrhythmia and those with severe renal impairment.
Potreban je oprez u liječenju bolesnika čije se postojeće bolesti mogu pogoršati zbog povišenja krvnog tlaka, hipokalemije (npr. bolesnici koji uzimaju srčane glikozide) ili retencije tekućine (npr. bolesnici sa zatajenjem srca), u bolesnika s teškom ili nestabilnom anginom pektoris, nedavnim infarktom miokarda ili ventrikularnom aritmijom, te u bolesnika s teškim oštećenjem bubrega.
Caution is required when Oncaspar is given in combination with other hepatotoxic substances, especially if there is pre-existing hepatic impairment.
Potreban je oprez kada se Oncaspar daje u kombinaciji s ostalim hepatotoksičnim tvarima, naročito ako već postoji oštećenje jetre.
Caution is required when ONIVYDE is given in combination with other hepatotoxic medicinal products, especially in patients with pre-existing hepatic impairment.
Oprez je potreban kada se ONIVYDE daje u kombinaciji s drugim hepatotoksičnim lijekovima, naročito u bolesnika s već postojećim oštećenjem jetre.
Caution is therefore advised when using medicinal products such as anti-hypertensives and/or cardiac glycosides concomitantly with brimonidine.
Savjetuje se stoga oprez pri istodobnoj primjeni brimonidina s lijekovima poput antihipertenziva i/ili srčanih glikozida.
Caution is therefore needed when anticoagulants such as coumarin, heparin, dipyridamole, acetylsalicylic acid or nonsteroidal anti-inflammatory drugs are given concomitantly.
Stoga je potreban oprez kada se istodobno primjenjuju antikoagulansi kao što su kumarin, heparin, dipridamol, acetilsalicilatna kiselina ili nesteroidni protuupalni lijekovi.
Caution is to be taken in patients with known hypersensitivity to other bisphosphonates.
Nalaže se oprez pri liječenju bolesnika s poznatom preosjetljivošću na druge bisfosfonate.
Caution is warranted and
Kod istodobne primjene
Caution is warranted and
Ne preporučuje se
Caution is warranted and
Nužan je oprez, te ako je dostupno,
Caution is warranted and
Potreban je oprez te se preporučuje
Caution is warranted and clinical
Potreban je oprez i preporučuje se
Caution is warranted and clinical monitoring is
Nalaže se oprez i preporučeno je kliničko
Caution is warranted and clinical monitoring is
Nalaže se oprez i preporučuje kliničko
Caution is warranted and clinical monitoring is recommended during co-administration.
U slučaju istovremene primjene preporučuju se primjena mjera opreza i klinički nadzor.
Caution is warranted and clinical monitoring is recommended during the co-administration.
U slučaju istovremene primjene preporučuju se primjena mjera opreza i klinički nadzor.
Caution is warranted and clinical monitoring is recommended upon co-administration of these antiarrhythmic medicinal products with Tybost.
U slučaju istovremene primjene ovih antiaritmičkih lijekova s lijekom Tybost preporučuju se primjena mjera opreza i klinički nadzor.
Caution is warranted and clinical monitoring is recommended when combined with boosted PREZISTA.
Potreban je oprez i preporučuje se kliničko praćenje kada se kombinira s pojačanom PREZISTOM.
Caution is warranted and clinical monitoring is recommended, when co-administration of clotrimazole is required.
Potreban je oprez i preporučuje se kliničko praćenje kada se zahtijeva istodobna primjena klotrimazola.
Caution is warranted and clinical monitoring is recommended.
Nalaže se oprez i preporučuje se kliničko praćenje.
Caution is warranted and clinical monitoring of
Nalaže se oprez i preporučuje kliničko
Caution is warranted and close
Na temelju opaženih odnosa
Caution is warranted and close
Potreban je oprez i preporučuje se pomno
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when co-administered with INTELENCE.
Kada se antiaritmici primjenjuju istovremeno s INTELENCEom opravdan je oprez i ako je moguće nadzor terapijske koncentracije antiaritmika.
Caution is warranted and therapeutic drug concentration monitoring is recommended when
Nužan je oprez, a preporučuje se i terapijsko praćenje koncentracije lijekova, ukoliko je moguće.
Caution is warranted and therapeutic drug concentration monitoring is recommended when available.
Nužan je oprez, a preporučuje se i terapijsko praćenje koncentracije lijekova, ukoliko je ono moguće.
Caution is warranted and therapeutic drug monitoring of digoxin concentrations, if available, is recommended in case of co- administration of lopinavir/ritonavir and digoxin.
Pri istodobnoj primjeni lopinavira/ritonavira i digoksina nužan je oprez, a preporučuje se i terapijsko praćenje koncentracije digoksina, ukoliko je ono moguće.
Caution is warranted and therapeutic drug monitoring of digoxin concentrations, if available, is recommended in case of co-administration of Kaletra and digoxin.
Pri istodobnoj primjeni lijeka Kaletra i digoksina nužan je oprez, a preporučuje se i terapijsko praćenje digoksina, ukoliko je moguće.
Caution is warranted and therapeutic drug monitoring of digoxin concentrations, if available, is recommended in case of co-administration of Kaletra and digoxin.
Pri istodobnoj primjeni lijeka Kaletra i digoksina nužan je oprez, a preporučuje se i terapijsko praćenje digoksina, ukoliko je ono moguće.
Caution is warranted and therapeutic drug monitoring of digoxin concentrations, if available, is recommended in case of co-administration of Kaletra and digoxin.
Pri istodobnoj primjeni lijeka Kaletra i digoksina nužan je oprez, a preporučuje se i terapijsko praćenje koncentracije digoksina, ukoliko je ono moguće.
Caution is warranted if mild CYP3A inducers are used concomitantly with Bosulif.
Potreban je oprez ako se s Bosulifom istodobno primjenjuju blagi induktori CYP3A.
Caution is warranted if Onglyza is used in patients who have known risk factors for hospitalization for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Potreban je oprez ako se Onglyza primjenjuje u bolesnika s poznatim čimbenicima rizika za hospitalizaciju zbog zatajenja srca, kao što je anamneza zatajenja srca ili umjereno do teško oštećenje funkcije bubrega.
Caution is warranted if Onglyza is used in patients who have known risk factors for hospitalization for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Potreban je oprez ako se Onglyza primjenjuje u bolesnika s poznatim čimenicima rizika za hospitalizaciju zbog zatajenja srca, kao što je anamneza zatajenja srca ili umjereno do teško oštećenje funkcije bubrega.
Caution is warranted if Qtern is used in patients who have known risk factors for hospitalization for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Potreban je oprez kada se Qtern daje bolesnicima s poznatim faktorima rizika za hospitalizaciju zbog zatajenja srca, kao što su zatajenje srca ili umjereno do teško oštećenje bubrežne funkcije u anamnezi.
Caution is warranted if this medicinal product is used in patients who have known risk factors for hospitalization for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Potreban je oprez ako se ovaj lijek primjenjuje u bolesnika s poznatim čimbenicima rizika za hospitalizaciju zbog zatajenja srca, kao što je anamneza zatajenja srca ili umjereno do teško oštećenje funkcije bubrega.
Caution is warranted if Tyverb is prescribed to patients with moderate or severe hepatic impairment (see sections 4.2 and 5.2).
Neophodan je oprez pri primjeni lijeka Tyverb u bolesnika s umjerenim do teškim oštećenjem funkcije jetre (vidjeti dijelove 4.2 i 5.2).
Caution is warranted when Cubicin is co-administered with tobramycin.
Potreban je oprez tijekom istodobne primjene Cubicina i tobramicina.
Caution is warranted when prescribing CRESEMBA to patients taking other medicinal products known to decrease the QT interval, such as rufinamide.
Potreban je oprez kod propisivanja lijeka CRESEMBA bolesnicima koji uzimaju druge lijekove za koje se zna da skraćuju QT interval poput rufinamida.
Caution is warranted.
Potreban je oprez.
Caution must be demonstrated if the patient:
Potrebno je pristupiti s oprezom ako bolesnik:
Caution must be exercised if clinical circumstances require combining stiripentol with substances metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. several HIV protease inhibitors, antihistamines, astemizole, chlorpheniramine, calcium channel blockers, statins, oral contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section for antiepileptic medicines).
Mora se biti oprezan u slučaju kad kliničke okolnosti zahtijevaju kombiniranje stiripentola s tvarima koje metabolizira CYP2C19 (na primjer citalopram, omeprazol) ili CYP3A4 (kao što su inhibitori HIV proteaze, antihistaminici poput astemizola, klorfeniramina, blokatori kalcijskih kanala, statini, oralni kontraceptivi, kodein) zbog povećanog rizika od nuspojava (vidjeti nadalje u ovom dijelu za antiepileptičke lijekove).
Caution must be exercised in patients ≥ 85 years of age as there is limited experience in this age group.
Potreban je oprez kod primjene u bolesnika u dobi ≥ 85 godina, jer su iskustva s primjenom u populaciji te starosne dobi ograničena.
Caution must be exercised in these patients and dose adjustment may be necessary (see section 5.2).
Kod primjene u tih bolesnika potreban je oprez i može biti potrebno prilagođavanje doze (vidjeti dio 5.2).
Caution must be exercised in treating patients with mild to moderate hepatic impairment, and a slower titration of Zonisamide Mylan may be required.
Treba postupati oprezno u liječenju bolesnika s blagim do umjerenim oštećenjem jetre i može biti potrebna sporija titracija lijeka Zonisamid Mylan.
Caution must be exercised in treating patients with renal impairment, as there is limited information on use in such patients and a slower titration of Zonisamide Mylan might be required.
U liječenju bolesnika s oštećenjem bubrega treba postupati oprezno jer su podaci o primjeni u takvih bolesnika ograničeni i mogle bi biti potrebne sporije titracije lijeka Zonisamid Mylan.
Caution must be taken in any patient with a history of seizures.
Oprez je potreban kod svih pacijenata s napadajima u anamnezi.
Caution regarding potential concomitant immune effects is required when switching patients from teriflunomide to TYSABRI.
Kada bolesnici prelaze s teriflunomida na TYSABRI, potreban je oprez zbog mogućih istodobnih imunoloških učinaka.
Caution required with concomitant use CYP3A4 inhibitors
Oprez potreban kod istodobne primjene CYP3A4 inhibitori
Caution required with concomitant use P-gp interactions
Istodobna primjena zahtijeva oprez P-gp interakcije
Caution should also be exercised in patients diagnosed or suspected to have Congenital Long QT Syndrome or acquired QT prolongation or patients on concomitant medications known to prolong the QT interval, induce electrolyte abnormalities or known to increase tacrolimus exposure (see section 4.5).
Potreban je također oprez u bolesnika s dijagnozom ili sumnjom na kongenitalni sindrom produženog QT-a, stečenog produljena QT-a ili u bolesnika na istovremenoj terapiji za koju se zna da produžuje QT interval, uzrokuje poremećaje elektrolita ili povećava izloženost takrolimusu (vidjeti dio 4.5).
Caution should also be taken with co-administration with beta-blockers or digoxin.
Oprez je nužan i kod istodobne primjene beta-blokatora ili digoksina.
Caution should be
Potreban je oprez kad se
Caution should be
Potreban je oprez u bolesnika
Caution should be exercised and a reduction of the starting dose of Iclusig to 30 mg should be considered with concurrent use of strong CYP3A inhibitors such as clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit juice.
Treba biti oprezan i razmotriti smanjenje početne doze lijeka Iclusig na 30 mg kod istovremene primjene s jakim inhibitorima CYP3A kao što su klaritromicin, indinavir, itrakonazol, ketokonazol, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, troleandomicin, vorikonazol i sok grejpfruta.
Caution should be exercised and additional International Normalized Ratio (INR) monitoring is recommended when dabrafenib is used concomitantly with warfarin and at discontinuation of dabrafenib (see section 4.5).
Potreban je oprez kod istovremene primjene dabrafeniba i varfarina, te se preporučuju dodatne kontrole INR-a (International Normalized Ratio), kao i nakon prekida primjene dabrafeniba (vidjeti dio 4.5).
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Potreban je oprez i kontrola u bolesnika s povišenim ALT-om i/ili AST- om, u bolesnika sa znakovima i simptomima oštećenja jetre, u bolesnika s prethodno postojećim stanjima povezanima s ograničenom funkcionalnom rezervom jetre te u bolesnika koji se liječe potencijalno hepatotoksičnim lijekovima.
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Potreban je oprez i kontrola u bolesnika s povišenim ALT-om i/ili AST-om, u bolesnika sa znakovima i simptomima oštećenja jetre, u bolesnika s prethodno postojećim stanjima povezanim s ograničenom funkcionalnom rezervom jetre te u bolesnika koji se liječe potencijalno hepatotoksičnim lijekovima.
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Potreban je oprez i kontrola u bolesnika s povišenim ALT-om i/ili AST-om, u bolesnika sa znakovima i simptomima oštećenja jetre, u bolesnika s prethodno postojećim stanjima provezamina s ograničenom funkcionalnom rezervom jetre te u bolesnika koji se liječe potencijalno hepatotoksičnim lijekovima.
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST,in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Potreban je oprez i kontrola u bolesnika s povišenim ALT-om i/ili AST-om, u bolesnika sa znakovima i simptomima oštećenja jetre, u bolesnika s prethodno postojećim stanjima provezamina s ograničenom funkcionalnom rezervom jetre te u bolesnika koji se liječe potencijalno hepatotoksičnim lijekovima.
Caution should be exercised and follow-up organized in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Potreban je oprez i kontrola u bolesnika s povišenim ALT i/ili AST, u bolesnika sa znakovima i simptomima oštećenja jetre, u bolesnika s prethodno postojećim stanjima povezanim s ograničenom funkcionalnom rezervom jetre te u bolesnika koji su liječeni potencijalno hepatotoksičnim lijekovima.
Caution should be exercised and patients closely observed for bosentan- related toxicity.
Potreban je oprez i pažljivo promatranje pacijenata zbog toksičnosti povezane s bosentanom.
Caution should be exercised as cases of late occurrence of first neurological events in the second cycle have been observed.
Potreban je oprez jer su opaženi slučajevi kasne pojave prvih neuroloških događaja u drugom ciklusu.
Caution should be exercised in
Oprez je nužan kada se Kaletra
Caution should be exercised in
Potreban je oprez kada se afatinib
Caution should be exercised in administering clarithromycin with Kaletra to patients with impaired hepatic or renal function.
Kod bolesnika s oštećenom funkcijom jetre ili bubrega nužan je oprez pri istodobnoj primjeni klaritormicina i lijeka Kaletra.
Caution should be exercised in administering clarithromycin with Kaletra to patients with impaired hepatic or renal function.
Kod bolesnika s oštećenom funkcijom jetre ili bubrega nužan je oprez pri istodobnoj primjeni klaritromicina i lijeka Kaletra.
Caution should be exercised in administering clarithromycin with lopinavir/ritonavir to patients with impaired hepatic or renal function.
Kod bolesnika s oštećenom funkcijom jetre ili bubrega nužan je oprez pri istodobnoj primjeni klaritromicina i lopinavira/ritonavira.
Caution should be exercised in co- administering CYP3A4 inhibitors (e.g. ketoconazole, macrolide antibiotics, diltiazem) with tolvaptan (see section 4.4).
Treba biti oprezan kada se daju istovremeno inhibitori CYP3A4 (npr. ketoconazol, makrolidni antibiotici, diltiazem) i tolvaptan (vidjeti dio 4.4).
Caution should be exercised in co-administering CYP3A4 inducers (e.g. rifampicin, barbiturates) with tolvaptan.
Treba biti oprezan kada se induktor CYP3A4 (npr: rifampicin, barbiturat) daje istovremeno s tolvaptanom.
Caution should be exercised in co-administering CYP3A4 inducers (e.g. rifampicin, barbiturates) with tolvaptan.
Treba biti oprezan kada se induktor CYP3A4 (npr: rifampicin, barbiturate) daje istovremeno s tolvaptanom.
Caution should be exercised in coadministration of fesoterodine with other antimuscarinics and medicinal products with anticholinergic properties (e.g. amantadine, tri-cyclic antidepressants, certain neuroleptics ) as this may lead to more pronounced therapeutic- and side-effects (e.g. constipation, dry mouth, drowsiness, urinary retention).
Potreban je oprez kod istovremene primjene fesoterodina s drugim antimuskarinskim lijekovima i ostalim lijekovima s antikolinergičkim svojstvima (npr. amantadin, triciklički antidepresivi, određeni neuroleptici), jer to može dovesti do izraženijih terapijskih učinaka i nuspojava (npr. konstipacija, suha usta, omamljenost, retencija mokraće).
Caution should be exercised in patients at risk, such as the elderly, patients with cirrhosis of the liver or patients concomitantly treated with medications known to cause hyponatraemia.
Potreban je oprez u rizičnih bolesnika, kao što su stariji, bolesnici s cirozom jetre ili bolesnici istodobno liječeni lijekovima za koje je poznato da prouzročuju hiponatremiju.
Caution should be exercised in patients co-infected with hepatitis B or C virus due to the current limited data available.
Potreban je oprez kod bolesnika koji istodobno imaju infekciju virusom hepatitisa B ili C, s obzirom na to da su trenutno raspoloživi podaci ograničeni.
Caution should be exercised in patients on 5- or 8-methoxypsoralen (5 and 8-MOP), which increases melatonin levels by inhibiting its metabolism.
Potreban je oprez u bolesnika koji uzimaju 5- ili 8-metoksipsoralen (5- i 8-MOP), koji povećava razinu melatonina tako što inhibira njegov metabolizam.
Caution should be exercised in patients on cimetidine a CYP2D inhibitor, which increases plasma melatonin levels, by inhibiting its metabolism.
Potreban je oprez u bolesnika koji uzimaju cimetidin, inhibitor CYP2D, koji povećava razine melatonina u plazmi tako što inhibira njegov metabolizam.
Caution should be exercised in patients on fluvoxamine, which increases melatonin levels (by 17-fold higher AUC and a 12-fold higher serum Cmax) by inhibiting its metabolism by hepatic cytochrome P450 (CYP) isozymes CYP1A2 and CYP2C19.
Potreban je oprez u bolesnika koji uzimaju fluvoksamin, koji povećava razinu melatonina (17 puta veća AUC i 12 puta veća serumska Cmax) tako što inhibira njegov metabolizam putem izoenzima CYP1A2 i CYP2C19 jetrenog citokroma P450 (CYP).
Caution should be exercised in patients on oestrogens (e.g. contraceptive or hormone replacement therapy), which increase melatonin levels by inhibiting its metabolism by CYP1A1 and CYP1A2.
Potreban je oprez u bolesnica koje uzimaju estrogene (npr. kontracepcijske tablete ili hormonsku nadomjesnu terapiju) jer estrogeni povisuju razinu melatonina tako što inhibiraju njegovo metaboliziranje putem CYP1A1 i CYP1A2.
Caution should be exercised in patients receiving cardiac glucosides due to the risk of digitalis toxicity if hypercalcemia develops (see section 4.5).
Potreban je oprez u bolesnika koji uzimaju srčane glikozide zbog rizika od toksičnosti digitalisa ako se razvije hiperkalciemija (vidi dio 4.5)
Caution should be exercised in patients receiving concurrent administration of ONIVYDE with irradiation.
Potreban je oprez u bolesnika koji primaju ONIVYDE istovremeno sa zračenjem.
Caution should be exercised in patients receiving spinal and (or) epidural anaesthesia.
Potreban je oprez u bolesnika kod kojih se primjenjuje spinalna i (ili) epiduralna anestezija.
Caution should be exercised in patients receiving spinal and (or) epidural anaesthesia.
Potreban je oprez u bolesnika kod kojih se primjenjuje spinalna i (ili) epiduralna anesteziju.
Caution should be exercised in patients receiving spinal and (or) epidural anaesthesia.
Potreban je oprez u bolesnika u kojih se primjenjuje spinalna i (ili) epiduralna anestezija.
Caution should be exercised in patients that have previously shown hypersensitivity reactions to cefovecin, other cephalosporins, penicillins, or other drugs.
Posebne mjere opreza treba poduzeti kod pacijenata koji su prethodno već imali hipersenzitivne reakcije na cefovecin, druge cefalosporine, peniciline i ostale lijekove.